Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 5th International Conference on Clinical & Experimental Dermatology New Orleans, USA.

Day 1 :

Keynote Forum

Martin C. Mihm

Brigham & Women’s Hospital
USA

Keynote: Pathogenesis and comparison of atypical spitz nevi vs benign spitz, and childhood melanoma

Time : 10:05-10:35

Conference Series Dermatology-2015 International Conference Keynote Speaker Martin C. Mihm photo
Biography:

Martin C Mihm graduated “Summa cum laude” from Duquesne University in 1955. He obtained his medical degree from the University of Pittsburgh Medical Center in 1961. He specialized in Internal Medicine, Dermatology, Pathology, and Dermatopathology. He started residency in dermatology at the Massachusetts General Hospital (MGH) in 1964 and after completing pathology residency joined the staff in 1973. In 1976, he founded one of the first five residency training programs in Dermatopathology in the United States. He became a Professor at Harvard Medical School in 1980. He joined the faculty of Albany Medical Center in 1993 to establish a dermatology and dermatopathology training program. In 1996, he returned to MGH to continue work in melanoma and to establish a vascular malformation clinic as Clinical Professor. On July 1, 2010, he assumed the position as Director of the Melanoma Program in Dermatology at the Brigham and Women’s Hospital and Associate Director Dana-Farber and Brigham and Women’s Cancer Center. He holds now five adjunct professorships at different schools in the United States. He also was a co-founder of the Rare Tumor Institute of the WHO in Milan, Italy and acted as external coordinator for five years. He is currently co-director of the EORTC melanoma pathology program. He has written over four hundred articles and authored and co-authored twelve books. His research interests have principally been related to malignant melanoma, the study of delayed hypersensitivity reactions in animals and humans with Dr. Harold Dvorak, and more recently has begun to investigate the pathogenesis of vascular anomalies. He began his melanoma studies with Dr. Wallace Clark in 1965 and coauthored the first publication of the classification of malignant melanoma into subtypes.

Abstract:

This presentation will review the clinical and pathologic features of the Spitz group of lesions that cause both clinical and histopathological difficulties in diagnosis. The clinical features of each entity will be described, followed by the appropriate histopathologic criteria that will also be illustrated. The benign Spitz nevus will be compared to atypical Spitz nevi, and atypical Spitz’s tumors. Many of the latter lesions have the ability to metastasize but usually do not extend beyond regional lymph nodes. The criteria for the diagnosis of the atypical Spitz’s tumor will be presented in detail. The malignant counterpart of the Spitz nevus will also be described. The treatment of each entity will be presented. A recently described entity, considered by many a variant of the Spitz nevus, the so-called BAPoma, will also be shown in clinical and histopathologic detail. The mutation that results in this tumor will be discussed, as well as the heritable nature of patients affected by this trait. Finally, the second portion of the talk will review malignant melanoma of childhood, its incidence, clinical presentation, and histopathology. Emphasis will be placed on the lesions that have the capacity to cause death in children. These lesions will be compared to and contrasted with the Spitz nevus and its associated atypical counterparts. Treatment of childhood melanoma will also be detailed. Recent molecular techniques including Frozen In-Situ Hybridization (FISH) will also be reviewed.

Keynote Forum

Clay J Cockerell

Founder of Cockerell Dermatopathology
USA

Keynote: Cutaneous melanoma

Time : 10:35-11:05

Conference Series Dermatology-2015 International Conference Keynote Speaker Clay J Cockerell photo
Biography:

Clay J. Cockerell, MD is Clinical Professor of Dermatology and Pathology at the University of Texas Southwestern Medical Center and Director of the Division of Dermatopathology. He is the President and Owner of Cockerell Dermatopathology and the past Medical Director of Cockerell and Associates Dermatopathology as well as a diplomat of the American Academy of Dermatology and American Board of Dermatopathology. Dr. Cockerell is internationally recognized for his contributions to both dermatology and dermatopathology. He is the past president of the American Academy of Dermatology. For many years, Dr. Cockerell has overseen an educational program designed to train the next generation of dermatopathologists. He has served as Associate Editor of the Journal of the American Academy of Dermatology and is on the editorial boards of a number of medical journals including the American Journal of Dermatopathology.

Abstract:

This talk presents an overview and update of what’s new in the diagnosis and treatment of Melanoma. Topics include the epidemiology, primary prevention, diagnosis, and treatment of melanoma. Emphasis placed on clinicohistopathologic correlation and novel genetic testing that can guide diagnosis, prognosis and treatment

Break: Networking & Refreshments Break 11:05-11:25 @ Foyer
  • Dermatopathology
Speaker
Biography:

I completed my medical education in Erciyes University Medical Faculty, Kayseri, Turkiye in 1989. My training of dermatology was in Dokuz Eylül University Medical Faculty, Izmir, Turkiye between 1992-1997. In my residency period I had worked hard on dermoscopy. So, I worked on my thesis entitled “Dermoscopy in Melanocytic Melanotic Lesions” between 1994-1997. This thesis was the first thesis on dermoscopy in Turkiye. I am currently a member of DermatovenereologyAssociation of Turkey, TurkishDermatologyAssociation, TurkishDermatopathologyAssociation, Turkish Skin andVenereologicDiseasesAssociation, International Society of Dermatology (ISD), European Academy of DermatologyandVenereology (EADV), American Academy of Dermatology (AAD) (Since 2001). Moreover, I am also a board member in International DermoscopySociety (IDS).

Abstract:

Targetoidhemosiderotichemangioma (THH), alsoknown as hobnailhaemangioma, is a benign,solitary, targetoidvascularneoplasmoccurringpredominantlyon theproximalextremitiesandtrunk. Mostpatientsexhibit a typical, targetoidhaemangioma,whereby a small, solitary, purpleand/orbrownpapule is surroundedby an ecchymotic ring that canexpandorsubsequentlydisappearwithpersistence ofthecentralpapule. Thehalo, however, is not a constantfinding, thusthetermhobnailhaemangiomawascoinedtodescribethenon-targetoidvariant of THH. Duration of thelesionsrangesfrom 1 monthto 20years. Duringthis time, THH mayundergoepisodicandcyclicchanges in morphology.Dermoscopyhas beenscarcelyused in thediagnosisof THH. Here wedescribeourcases of targetoidhemosiderotichemangioma, ndstudytheirmonthlychangingdermoscopicalfindingstoshowthatthistechniquecould be useful in themonitoringanddifferentialdiagnosis of thisscarcelyreportedentity.

Speaker
Biography:

Boglarka Balazs has graduated as pharmacist at the age of 23 years from University of Szeged, Faculty of Pharmacy. She is 2nd year Ph.D. student in University of Szeged, Doctoral School of Pharmaceutical Sciences. Her research fields are investigation of skin diseases with spectroscopy methods (ATR-FTIR, NIR and RAMAN), development of dermal and transdermal systems and electrically-assisted transdermal delivery. She spent one month with cooperative work in the „Victor Babes” University of Medicine and Pharmacy in Timisoara, Romania. She took three poster lectures and two articles are under review.

Abstract:

Psoriasis is a T lymphocyte-mediated inflammatory disorder that affects the skin. A number of studies have demonstrated the occurrence of lipid alterations in psoriatic skin, resulting in a highly perturbed stratum corneum (SC). Relatively little attention has been paid to the protein conformation of the SC. In this study, the Attenuated total reflection Fourier transform infrared (ATR-FTIR) spectrum of the untreated psoriatic patients unharmed SC was obtained after tape stripping. We focused on the amide-I band components in order to establish whether there are any protein alterations in the intact areas of psoriatic skin. Fourier self-deconvolution (FSD) of the amide-I band was followed by curve-fitting to generate the underlying components. Integration of band areas provided an estimate of the secondary structure. The results indicated decreases in all amide-I band components, the peak at 1660 cm-1 revealing the most dramatic change. The intensity of the peak at 1660 cm-1 decreases almost to zero in psoriatic patients for both males (p < 0.05*) and females (p < 0.01**). This peak is characteristic of the turn structure in the protein chain. The decrease is marked in the case of the β-sheet structure at 1630 cm-1 too. The protein structure is changed on the unaffected area in the psoriatic skin disease. This ATR-FTIR imaging is a rapid and simple noninvasive method promotes a better understanding of the disease, and would be helpful in following the treatment.

  • Veterinary Dermatology
Speaker
Biography:

Nasim Fazel, MD, DDS, MAS, Associate Professor of Dermatology, completed her medical school training at the University of Michigan, Ann Arbor followed by her dermatology training at Henry Ford Health System in Detroit, Michigan. Prior to her medical training she completed her dentistry training at Northwestern University Dental School. She has a unique background with dual certification in dermatology and dentistry. Dr. Fazel has a special interest in the medical management of oral mucous membrane disease and soft tissue pathology. Her background in dentistry provides for insight into the pathophysiology and treatment of aphthous ulcers, burning mouth syndrome, oral lichen planus, and oral vesiculobullous disease. Dr. Fazel is regarded as a leading expert in the field of oral mucosal disease by many colleagues who refer these difficult and challenging conditions to her.

Abstract:

Oral lichen planus (OLP) is an oral mucosal disease considered to be a pre-malignant condition with risk of malignant transformation to oral squamous cell carcinoma (SCC) at varying rates ranging from 0.8% to >5%. Studies of loss of heterozygosity and microsatellite instability indicate that OLP is molecularly distinct from oral dysplasias and SCC. The operating hypothesis for our studies is that tumors, such as SCC, arise through “malignant reprogramming” driven by a combination of both genetic and epigenetic changes. The primary goal of this pilot study is to identify key sites of aberrant epigenetic regulation in OLP by defining the entire repertoire of differentially-expressed genes and regulatory non-coding (ncRNAs) in OLP lesions. This is accomplished by performing state-of-the-art next-generation sequencing (NGS)-based whole transcriptome profiling (RNA-Seq) analyses of matched pairs of lesional and perilesional normal appearing tissue samples. The specimens were sectioned for RNA extraction, chromatin immunoprecipitation (ChIP), and immunohistological studies. Sequencing libraries prepared from the total RNA samples were sequenced on an Illumina HiSeq 2000 to yield ~30 million reads per sample, which will then be processed with our automated analysis pipeline. Subsequently, integrative bioinformatics was applied to define an OLP-specific gene expression signature, as well as application of gene set enrichment analysis to define potential overrepresentation of functional groups, including immune system and inflammatory pathway-related genes. Insight into the mechanistic basis engendering these expression changes was obtained by correlation with the occurrence of somatic mutations (variant analysis) and epigenetic changes, such as histone modifications. We anticipate that characterization of the latter will lead to the identification of the responsible histone-modifying enzymes, which can then be exploited as novel therapeutic targets.

  • Cosmetic Dermatoogy
Speaker
Biography:

Dr. Lin is a Professor and a Physician Scientist in the Department of Traditional Chinese Medicine (TCM) at Chang Gung Memorial Hospital (CGMH) in Taiwan. He started with CGMH in 1997 and is trained in both TCM and western medicine. His interests are to develop TCM herbs to treat skin diseases using modern scientific methods to provide the evidence base for TCM. During the past decade, he has published numerous articles in prominent international medical journals focused on using indigo naturalis in treating skin and nail psoriasis. His novel finding has attracted a great deal of media attention

Abstract:

Indigo naturalis has been used to treat skin psoriasis topically in Taiwan for years and has demonstrated significant improvements in skin psoriatic symptoms. Indigo naturalis has been used for centuries in traditional Chinese medicine to treat various inflammatory and infectious diseases, including psoriasis. Recently, a refined formula was developed from indigo naturalis and extracted in olive oil, Lindioil. To evaluate its effect on nail psoriasis, we conducted a randomized, observer-blind, intra-subject comparison trial to compare indigo naturalis extract in oil (Lindioil) to calcipotriol solution. Lindioil or calcipotriol was applied topically to 28 subjects’ two bilaterally symmetrical psoriatic nails twice daily for 24 weeks. Efficacy was assessed by single hand Nail Psoriasis Severity Index (shNAPSI) for five nails on one hand and modified target NAPSI (mtNAPSI) for the single most severely affected nail. The subject and physician’s global assessments (SGA and PGA, respectively) were measured at week 24. At week 24, the mixed-effect model revealed significant interactions between groups and time in shNAPSI (P < .0001) and mtNAPSI scores (P < .0001). The reductions in shNAPSI and mtNAPSI scores for the Lindioil group (49.5 ± 26.21%, 77.9 ± 16.41%) were superior to the calcipotriol group (24.9 ± 27.67%, 65.4 ± 17.27%). The subject and physician’s global assessments showed similar results and no adverse events were observed. This indicates that Lindioil is superior to calcipotriol and is a novel, safe and effective therapy for treating nail psoriasis for long-term use. Lindioil is the first botanical drug that demonstrates improvement in nail psoriasis.

Speaker
Biography:

Dr Rachita Dhurat is professor & head at department of Dermatology has published more than 40 articles in national & international journals. She has been invited to international conferences as a faculty. Her pioneer work on microneedling for androgenetic alopecia has got many accolades across the globe. • IADVL ( Indian association of dermatologists,venereologists & leprologists) • IASSTD( Indian association of study of sexually transmitted diseases) • International Academy of Cosmetic Society • Trichology Society of India • Cosmetic Society of India • Member of Asia – Pacific centre for aging skin (APCAS), for Proctor & Gamble Ltd Australia • Faculty for F1000- post peer publication review

Abstract:

Introduction – Androgenetic alopecia (AGA), is the most common type of alopecia in men, which is an androgen mediated event . Finasteride and minoxidil, which show cosmetically acceptable new hair growth in modest percentage of patients. Materials and Method: Hundred cases of AGA were recruited into weekly microneedling treatment with twice daily 5% minoxidil lotion (Microneedling group); other group was given only 5 % minoxidil lotion. The 3 primary efficacy parameters assessed were: hair count , patient assessment and 7- point evaluation scale.A stereotactic positioning device was used. . Microneedling Procedure – A dermaroller of 1.5 mm sized needles was rolled over the affected areas of the scalp till mild erythema was noted. All patients were instructed not to apply minoxidil on the day of procedure. Results: 1. Hair counts The mean change in hair count at week 12 was significantly greater for the Microneedling group compared to the Minoxidil group P< 0.05 2.Investigator evaluation Forty patients in Microneedling group had +2 to +3 response on 7-point visual analogue scale, while none showed the same response in the Minoxidil group. 3. Patient evaluation In the Microneedling group, 41(82%) patients reported more than 50% improvement versus only 2 (4.5%) patients in the Minoxidil group. Unsatisfied patients to conventional therapy for AGA got good response with Microneedling treatment. Other notable findings during the study period were - Initiation of new hair growth was noticeable by around 6 weeks in Microneedling group and by 10 weeks in Minoxidil group. Rapid growth in the existing hair was seen at week 1 in the Microneedling group than Minoxidil group. Conclusion: Dermaroller along with Minoxidil treated group was statistically superior to Minoxidil treated group in promoting hair growth in men with AGA for all 3 primary efficacy measures of hair growth. Microneedling is a safe and a promising tool in hair stimulation and also is useful to treat hair loss refractory to Minoxidil therapy. This is the first study of use of microneedling in male androgenetic alopecia.

Speaker
Biography:

Pamela Springer has over 20 years of experience working with African American, Asian and Hispanic skins. She has consulted with medical personnel and their support staff training on the similarities and differences of each ethnic group. Pamela has written, Natural Radiance: A Guide to Ethnic Skin Care, is a book reviewer for Milady’s Publishing and a Subject Matter Expert for the National Council of State Boards of Cosmetology, Inc (NIC). She was the first aesthetician to serve on the Arizona Board of Cosmetology. Contributing to industry publications has led her to become a sought-after speaker for the aesthetics, cosmetology and medical practitioners.

Abstract:

The goal of this activity is for health care and wellness providers to develop a greater understanding of the importance of assessing ethnic and cultural factors when performing skin assessments, developing skin treatment plans or consulting with individuals regarding basic or advanced skin care treatments. Current data suggests that ethically/racially diverse patients may be identified and diagnosed with skin cancer at later stages than other groups. The heart of the course is the development of a personal skin profile based on observation and quantitative methods. Consultation is the key to a truly comprehensive skin assessment and in this way supports not only skin health but the early identification of potential skin cancer risks

  • Track 9: Skin Infections and Prevention
    Track 10: Clinical and Medical Dermatology
Location: Ground Ball Room B

Chair

Alexander Zink

Technische Universitaet Muenchen
Germany

Speaker

Co-Chair

Zahide Eris Eken

Istanbul Bilim University School of Medicine, Turkey

Session Introduction

Zahide Eris Eken

Istanbul Bilim University School of Medicine
Turkey

Title: Mesotherapy and prp procedures in hair loss

Time : 09:00-09:20

Speaker
Biography:

Assistant Prof. Dr. Zahide Eris Eken was born in Aksaray, Turkey. She graduated from Istanbul University Cerrahpasa Faculty of Medicine as Medical Doctor. She completed the residency period of Dermatology in Istanbul Bezmi Alem Vakıf University, Faculty of Medicine, and Department of Dermatology. She is working Istanbul Bilim University, Faculty of Medicine, Sisli Florence Nightingale Hospital, and Department of Dermatology as a Assistant Prof.

Abstract:

Hair loss is a frequently seen embarrassing problem faced by people of all age groups and ethnicity. Factors that cause hair loss are genetic, environmental, pathological and psychological. Various treatment and cosmetic procedures gaining importance in the treatment of hair loss over time. Mesotherapy and PRP are also procedures that used in hair loss. There are a few studies about these techniques and their efficacy in relation with hair loss therapy. But these procedures have received a lot of publicity in the media and internet about its role in hair loss and androgenetic alopecia. Mesotherapy and PRP injections are made directly into the skin with mesogun or by hand once in 2-4 weeks. In hair loss some physicians use both of these procedures. Mesotherapy and PRP techniques and their uses in hair loss discussed in this presentation.

Speaker
Biography:

Karishma Hemmady has completed her MD in Dermatology from MGM Institute of Health Science from Mumbai, India in 2014. She has also completed her Diploma in practical Dermatology from Cardiff University, UK in 2013. She is a Specialist Registrar in the Department of Dermatology at MGM Hospital, and a board member and consulting dermatologist at Ultra Derm Clinic, Pune, Maharashtra, India. Being research oriented, she has presented and published more than 10 papers in reputed journals and conferences.

Abstract:

INTRODUCTION- Melasma is an acquired condition that presents as tan to brown hyperpigmented macules which coalesce to form patches on the forehead, cheeks, nose and chin resulting in cosmetic concern to patients. A clinical trial of intradermal injections of tranexamic acid for melasma proved to be efficacious. We postulate the use of microneedling system, like dermaroller TM, to increase efficacy of tranexamic acid delivery by creating micro-channels may be utilised for treating melasma. AIMS AND OBJECTIVES- • To study the safety and efficacy of transepidermal administration of tranexamic acid 100mg/ml in treatment of melasma. • To compare MASI scores, evaluated by a blinded investigator, at pre-treatment, week 2, week 4, and week 8. • To evaluate physician global assessment, by a blinded investigator, at pre-treatment, week 2, week 4, week 8. • To compare patient global assessment at pre-treatment, week 2, week 4 and week 8. • To report any adverse effects of the procedure and treatment. MATERIAL AND METHODS- Twenty patients, who fulfilled the inclusion criteria, were recruited for the split face prospective trial lasting 8 weeks. The test and control sides of the face of all subjects were randomised and one side received tranexamic acid 100mg/ml while the other side received placebo (normal saline solution.), after creating micro-channels with dermaroller. The procedure was repeated at weekly intervals. All patients were photographed prior to starting the procedure (base line photographs) and then at weekly intervals prior to the procedure. MASI scoring was evaluated at each follow up prior to commencing the procedure. RESULT-A total of 20 patients were enrolled for the study. There were no drop outs in the study and no adverse effects to the treatment modality were reported. There was a decreasing trend in the MASI results, which was evaluated by the blinded investigator, as the treatment continued on the test site as compared to placebo which remained static. The physician global assessment scores showed no significance in the placebo site however there was significant improvement in the test sites. The global assessment scores of the patients showed an improvement (p-value 0.001) in the test site as compared to the placebo sites which showed no significant trend (p-value more than 0.05). CONCLUSION- Transepidermal delivery of 100mg/ml tranexamic acid with microneedling is a new and promising procedure to treat melasma.

Nooshin Bagherani

Jundishapour University of Medical Sciences
Iran

Title: Introduction of a novel therapeutic option for atrophic acne scars: serum injection therapy

Time : 09:40-10:00

Speaker
Biography:

Nooshin Bagherani completed general medicine at Arak University of Medical Sciences, followed by training in Dermatology from Jundishapour University of Medical Sciences. She is also bachelor of law and student of oil engineering. She is one of the founders of the Association of the Students and Graduates of Markazi Province in Arak. Now she is the founder and Editor of "The World's Greatest Dermatology Atlas". She has authored more than 20 publications in peer-reviewed journals, one textbook and one chapter in another

Abstract:

Introduction and objective: Acne scars are extremely bothersome to patients and often challenging to treat. Regarding texture, they are divided into the scars with normal texture and the scars with atrophic texture. The acne scars with atrophic texture consist of ice pick, boxcarand rolled scars. Topical, physical, surgical, and light modalities, alone or in combination have been administered in the treatment of acne scars with variable results. Herein, for the first time I introduced serum injection therapy as a novel effective therapeutic option for the atrophic acne scars. Material and method: In this study, the patients with atrophic acne scars were selected among the patients had referred to my private dermatology office. After describing the process of the study, a written consent was acquired from them. I administered 0.9% sodium chloride serum in this study. After local anesthesia with lidocaine, the serum was injected intra- and sub-dermally in the regions of acne scars and skin pores. The amount of serum for injection was determined based on the severity of scars, so that it over-corrected the scars and widespread to the neighboring regions. In every session, before the procedure, photographs were taken from the patients. This process was done weekly for 5 weeks and topical alpha hydroxy acid-containing agents were prescribed beside this procedure. In every session, I objectively and subjectively assessed the results of treatment regarding the type of acne scar. In this study, for evaluating the response I used a visual score including in: scores1-3 as poor response, 4-6 as moderate response,7-9 as good response, and 10-12 as significant response.The subjective evaluation was acquired by questioning about the general success of treatment from the patients. For the objective evaluation, the photographs were observed. This observation included the assessment of response according to the type of acne scar. For every case, the objective and subjective scores in every session and the mean of these scoresafter the last session were considered for assessment of the response. At the end, the data was analyzed by the SPSS software. Result: Among the 12 cases studied, 10 (83.3%) cases were female and 2 (16.7%) cases were male. The minimum and maximum ages of patients were 18 and 56 years, respectively. Among the subjects, 6 (50%)and 1 (8.3%) patientshad unsuccessfully undergone laser therapy and microdermabrasion for treating their acne scars, respectively.Isotretinoin was simultaneously administered in 4 (33.3) patients with the active acne. The ice pick, boxcar and rolled scars, and large pores were seen in 4 (33.3%), 10 (83.3%), 8 (66.7%) and 6 (50%) of patients, respectively. The patients had Fitzpatrick's skin types of III and IV. After the first and fifth sessions, the mean subjective response scores were 7.1±1.2 and 10.2±1.08, respectively.In the objective assessment, the mean score responses were 6.7±1.5, 7.2±2.02, 7.0±1.8, and 7.2±1.01 for the ice pick, boxcar, rolled scars and pores, respectively. After the fifth session, these scores were 10.0±0.9, 10.9±1.01, 10.4±1.3, and 10.3±1.3, respectively.The response was better in the acne patients under oral isotretinoin therapy in comparison with other cases, but it was not statistically significant. No statistically significant difference in the response was reported regarding the age, gender, skin type, and severity of acne scar. The patients reported skin lightening and tightening, decreasing of wrinkles and eminent cheeks as side profits of this procedure. Mild ecchymosis was the only side effect was seen in about one third of patients. Conclusion: My study revealed that the response to serum therapywas significant in the large pores and all types of the atrophic acne scars. In comparison with the severe acne scar, the patients with mild and moderate scars showed better responses. This study showed that the serum injection therapy can be an effective therapeutic option for the atrophic acne scars with no significant side effects. In addition, my study revealed that this procedure can successfully be used in thetreatment of patients suffering from the large skin pores.

Speaker
Biography:

Hesham M Ahmad has completed his M.D. at the age of 25years and Ph.D. at the age of 32 years from Minia University, Minia, Egypt. He did his postdoctoral studies at Thomas Jefferson University School of Medicine, Philadelphia, PA, USA. He is the clinical director of Cocoon Medical Centre, Al-Ain, Abu Dhabi, U.A.E., a Dermatology and Aesthetic centre. He is also an assistant professor at Department of Dermatology at Minia University Hospital, Minia, Egypt. He has published more than 20 papers in reputed journals.

Abstract:

Many medications are available for treatment of scabies and pediculosis capitis including ivermectin. We compared the efficacy and safety of topical versus oral ivermectin in treatment of scabies and pediculosis capitis. A total of 62 patients with uncomplicated scabies and 62 patients with head lice infestation were included. Each group was further subdivided into: Group I received single topical application of 1% ivermectin and Group II received single dose of oral ivermectin. Treatment was repeated after one week for non responders and patients were evaluated weekly for 4 weeks. The clinical responses as well as side effects were reported weekly. The results of this study show that both topical and oral ivermectin demonstrate high efficacy and tolerability in treatment of scabies and pediculosis capitis. However, a single treatment of pediculosis capitis with topical ivermectin provides significantly higher cure of infestation and faster relief of pruritus than oral ivermectin. In addition, whether topical or oral ivermectin is used to treat scabies or head lice, a second dose is required in some cases to ensure complete eradication.

Break: Networking & Refreshments Break 10:20-10:35 @ Foyer
  • Young Researchers Forum
Location: Ground Ball Room B

Session Introduction

Xinyi Du

University of Cambridge
UK

Title: Do sunscreens protect us?

Time : 10:35-10:50

Speaker
Biography:

Xinyi Du, 27, graduated from Medicine at the University of Cambridge, UK in 2012. She is completing her training in general internal medicine in London, and is currently based at the Royal Marsden Hospital. She has an interest in public health and medical education and is additionally completing a Masters in Clinical Education at King’s College, London. Dr Douglas Maslin, 27, graduated with distinction from Medicine at the University of Cambridge, UK in 2012. He is an academic clinical fellow in medicine at Addenbrooke’s hospital, currently working clinically in oncology, while also researching cancer stem cell behaviours within the Cambridge biomedical campus. His main interest is in the prevention of dermatological malignancies – particularly melanoma. Additionally, Douglas is an associate fellow of the higher education academy, a teaching bye-fellow of Downing College, and is currently completing a Masters in Translational Therapeutics.

Abstract:

Sunlight stimulates a multitude of important biological effects on skin, causing, amongst other pathological changes, photocarcinogenesis. Sunscreens are designed to provide protection against these harmful properties of ultraviolet radiation, and public health campaigns have been employed to encourage their use. Despite this, there has been a continued rise in the incidence and mortality of the most harmful skin cancer, malignant melanoma. Although public health campaigns and mathematical models suggest sunscreen use would reduce incidence of all skin cancers, including melanoma, research so far has not provided clear-cut evidence that this is true. One randomized controlled trial found the daily use of sunscreen over 4½ years significantly reduced the incidence of squamous cell carcinoma but not of basal cell carcinoma. More recent studies have had similar results – the risk of squamous cell carcinoma is decreased, but the results for basal cell carcinoma are equivocal. Furthermore, some early research on melanoma has even suggested, controversially, that the application of sunscreen may even increase the risk of melanoma. However, the presence of confounding factors such as the potential inappropriate application of sunscreen and increased time of UV exposure in sunscreen users are not fully accounted for within these studies. We will explore the available evidence on both the beneficial and harmful effects of sunscreen use with practical advice on how we might advise our patients to best protect themselves from photocarcinogenesis.

Speaker
Biography:

Pilvi Maliniemi is currently a graduate student, who will be completing her PhD this year 2015 from the Medical Faculty of Helsinki University. She has already published eight (8) papers in reputed journals in the field of Mitochondrial Diseases and Molecular Oncology of Cutaneous T Cell Lymphomas.

Abstract:

Indoleamine-2,3-deoxygenase (IDO-1), catabolizing tryptophan(Trp) to kynurenine (Kyn), causes an immunosuppressive microenvironment in many neoplasias. In this study we identify the IDO-expressing cell subtypes in cutaneous T-cell lymphoma (CTCL) and determine the significance of serum Kyn/Trpcatabolite levels. IDO-1 mRNA and protein expression was studied in 68 FFPE skin samples of mycosis fungoides (MF), lymphomatoidpapulosis (LyP), lichen ruberplanus (LRP), and subcutaneous panniculitic-like T cell lymphoma (SPTL), and in three CTCL cell lines. For co-expression, anti-CD33 (myeloidderived suppressor cells, MDSC) and anti-CD163 (tumor-associated macrophages, TAM) antibodies were used. Levels of 14 Trp metabolites were measured in 69 patient and healthy control sera by liquid chromatography–tandem mass spectrometry (LC-MS/MS). The relative expression of IDO-1 mRNA was markedly elevated in MF and LyP samples compared to LRP and also in the MF-derived cell line MyLa compared to the CD30+ CTCL lines Mac-1 and Mac-2A. Interestingly, IDO was co-expressed by CD33+ MDSCs in MF and in LyP and by the CD163+ TAMS in SPTL. The increase of IDO also associated with the eleveted level of Treg cells in LyP as 50% of the cases studied showed a moderate or strong FoxP3 expression. Serum Kyn/Tryp ratios showed significant increase in MF (p<0.05) compared with those of healthy controls and correlated with MF activity. We show that IDO is produced by the MF cell line MyLa and by CD33+ MDSCs in MF and in LyP but instead by CD163+ TAMs in SPTL. FoxP3+ Tregs, abundant in LyP, may contribute to the indolent clinical behavior. Serum Kyn/Tryp ratio in MF associates to a progressive disease behavior and may be a useful clinical indicator.

Speaker
Biography:

Manjit Kaur has completed her MBBS from Baba Farid University of Health Sciences, Faridkot, India in 2006 and Masters in Dermatology & STDs from the same University at the age of 27 years. She stood first in Postgraduate University Examination. She has worked as a Senior Consultant at Kaya Skin Clinic for two years and as a Senior Resident at Government Medical College, Chandigarh for three years. She is a life member of IADVL, CSI and ACSI. She has presented papers in Award Paper session, Young Dermatologist Forum, free papers and Posters in national and regional dermatology conferences.

Abstract:

Vitiligo is an acquired, progressive depigmentation disorder of the skin and or mucous membranes of great cosmetic importance. Many new therapeutic options for vitiligo (both medical and surgical) have become available over the last decade. One among them is the smashed skin grafting or smash grafting which is a modification of split-thickness grafting. In this procedure, the graft undergoes smashing before being applied to the recipient site. Although it is a simple and effective procedure but very few people are doing it either due to lack of awareness or due to lack of published data. Objective of this study was to evaluate the effectiveness and safety of smash grafting in cases of stable vitiligo. Smash grafting was done in thirty cases of localized, stable, recalcitrant vitiligo in the present study. Patients were divided into group A (PUVA was given postoperatively) and group B (only sunlight exposure was given post operatively) and were followed up at four, eight, twelve weeks to assess repigmentation with the surrounding skin. In all 30 cases, repigmentation was observed from 3 weeks onwards and continued to increase on subsequent follow-ups. 76.66% of patients achieved more than 50% repigmentation at 12 weeks. Although number of study cases was small and also the follow up period was short (only 12 weeks), Smash grafting was found to be a simple, easy to learn and cost effective one stage procedur

Pragati Gogia

Government Medical College and Hospital
India

Title: Therapeutic efficacy of intralesional tuberculin in the treatment of Verruca vulgaris

Time : 11:20-11:35

Speaker
Biography:

Dr Pragati Gogia has completed her MBBS from Mauritian University with rank 3 in 1st professional and rank 1 in 3rd professional and distinction in anatomy and ENT. She is currently pursuing DNB dermatology from Government medical college and hospital, Chandigarh, India. She is a member of IADVL.

Abstract:

Reem Saeed Alshehri

University of Tabuk
KSA

Title: Quality of life in atopic dermatitis patients

Time : 11:35-11:50

Speaker
Biography:

Reem Saeed Alshehri is graduated Medical Student, Faculty of Medicine, Tabuk University. She has a commitment and appreciation for mentoring and volunteering. She served as a Volunteer in Breast Cancer Convoy to the poor villages outside Tabuk. She has been participated in planning & organization for awareness programs for her University and community. She has completed two in-depth research studies, one being a study of the impact of phototherapy and a broader study on the quality of life in atopic dermatitis patients. She is a Member in Dermatology Student Club.

Abstract:

One of the most common conditions of the skin is Atopic dermatitis (AD) which usually occurs in infants but can also occur among children and adults. The predefined aim of the study was to analyze the affects of AD on the quality of life (QOL) of children or adults and to recognize the most affected areas of a patient’s life. QOL is an expansive concept and covers various dimensions of the human life that deals with the understanding of impacts that a disease can have on the QOL of an individual. It also tries to comprehend the outcomes associated with the treatment of patient and the burden of disease. Currently, the awareness regarding the measurement of QOL has augmented as it would be helpful for the physicians to have awareness regarding the patient’s views about their illness and its impact on their well being. In order to understand the impact of AD on the patient’s life and to understand whether the QOL of the public differs from that of the AD patient, evaluation of the QOL is imperative in the clinical field. The research in this regard is mandatory to make better decisions regarding resource allocation in dermatology to prevent it from suffering the consequences of lack of knowledge. Life threatening conditions as well as social and psychological consequences of this disease has not been documented yet but information regarding its impact on QOL will be helpful in overcoming this disease.

  • Track 1: Dermatological Diseases
    Track 2: Esthetic and Cosmetic Dermatology
Location: Ground Ball Room B
Speaker

Chair

Alwyn Rapose

Reliant Medical Group, USA

Speaker

Co-Chair

Nasim Fazel

University of California, Davis, USA

Session Introduction

Ajay K Banga

Mercer University
USA

Title: Microneedle and iontophoresis based products

Time : 11:25-11:45

Speaker
Biography:

Ajay K Banga is Professor and Department Chair in the Department of Pharmaceutical Sciences at the College of Pharmacy and Health Sciences, Mercer University, Atlanta, GA. He also holds an Endowed Chair in transdermal delivery systems. He has a PhD in Pharmaceutics from Rutgers University, NJ. He has over 250 publications and scientific abstracts to his credit. He currently serves on the Editorial Board of 10 journals, as Associate Editor for one journal, and has served as the Editor-in-Chief for a Drug Delivery Journal. He has written three single author books and over 10 book chapters in the areas of transdermal delivery and protein formulation/delivery. He is a Fellow of the American Association of Pharmaceutical Scientists.

Abstract:

In recent years, there has been increasing interest in active energy or minimally invasive technologies for cosmetic use and also to expand the scope of transdermal delivery to hydrophilic molecules and macromolecules. These molecules do not normally pass through the skin unless enabling technologies are used. Recent innovations in these technologies, especially for iontophoresis and microporation, will be presented. Microporation involves the creation of micron-sized micropores or microchannels in the skin which can then allow the transport of water soluble molecules. Skin microporation can be achieved by microneedles or by using thermal, laser, or radio-frequency ablation. Iontophoresis involves the application of small amounts of physiologically acceptable currents to drive ionic molecules into the skin. Technology behind products on the market such as Biobliss, Dermaroller, WrinkleMD and Zecuity will be discussed. The author has done significant research with both techniques in his laboratory with over 50 different drug molecules and cosmeceuticals.

Alwyn Rapose

Reliant Medical Group
USA

Title: Antibiotics for skin infections

Time : 11:45-12:05

Speaker
Biography:

Alwyn Rapose obtained his Doctorate in Dermatology/ Venereology / Leprology from King Edward VII Memorial Hospital, Bombay, India. Thereafter he obtained an MD in Internal Medicine from St. Vincent Hospital, Massachusetts, USA, followed by a Fellowship in Infectious Diseases at the University of Texas Medical Branch, Galveston, Texas, USA. He was a recipient of the NIH/NIAID supported UTMB postdoctoral research grant in Emerging and Reemerging Infectious Diseases. In July 2014 he was elected fellow of the American College of Physicians. He is presently Assistant Professor of Clinical Medicine at the University of Massachusetts, USA and practices as consultant in Infectious Diseases and Travel Medicine at the Reliant Medical Group and St. Vincent Hospital in Massachusetts, USA. Dr. Rapose is board certified in both Infectious Diseases and Internal Medicine.

Abstract:

Infections of the skin can be caused by bacteria, fungus, virus and rarely parasites. Bacterial skin infections can be mild - like impetigo and folliculitis, managed with topical medications, or severe – like abscess and necrotizing fasciitis requiring surgery, hospitalization and intravenous antibiotics. Over the last decade, there has been an increase in the number of severe bacterial skin infections - often associated with methicillin-resistant-staphylococcus-aureus (MRSA) - resulting in increased number of visits to emergency rooms. There is also a trend towards increasing hospital admissions for skin and skin-structure infections resulting in increased health-care costs. Host factors like diabetes, peripheral vascular disease as well as obesity contribute to the morbidity associated with these infections. Surgical site infections deserve special attention as the organisms associated with these are often acquired from the health-care environment. Early intervention with appropriate antibiotics results in improved outcomes. Deep wound cultures help target antibiotics to the organism identified. Outpatient intravenous antibiotic therapy (OPAT) has helped reduce duration of hospital stay. Vancomycin is considered the “gold-standard” for management of MRSA infection, but newer oral and intravenous antibiotics with improved safety profiles have expanded options for management of these infections.

Lorraine L. Rosamilia

Dermatologist, Geisinger Health System, State College, PA

Title: Herpes Zoster: Conundrums and controversies

Time : 12:25-12:45

Speaker
Biography:

Dr. Rosamilia is a Staff Dermatologist with the Geisinger Health System, practicing in State College, PA. She received medical school and residency training in dermatology at the Penn State Milton S. Hershey Medical Center in Hershey, PA, and has particular interest in resident and primary care teaching and scientific journal editing. Her practice focus includes medical dermatology, namely psoriasis, acne, infectious disease, and skin malignancy.

Abstract:

Herpes zoster presents significant clinical and fiscal morbidity for patients and providers. From acute and chronic wound and pain conditions to vaccination strategies and infection control measures, its ramifications intertwine between many medical disciplines and governing bodies. A recent study of health care economic burden notes that herpes (including zoster) is one of the top 5 most costly categories of skin disease. Moreover, medical providers differ widely in their approaches to the management of herpes zoster. For instance, the literature wavers in its recommendations for prevention of post-herpetic neuralgia, yet a well-done recent study has shed light on the effectiveness of antiviral and gabapentin regimens. Also, vaccination strategies for herpes zoster are inconsistent. It is currently recommended in patients over 50, and very few surveys have evaluated patient compliance since its FDA approval. In current clinical settings, it is unclear who should be taking the lead (primary care vs. specialists) for its employment, despite its positive safety and efficacy profile. In addition, hospital isolation policies for patients and staff with or exposed to herpes zoster are often inconsistent, misunderstood, outdated, or poorly outlined in institutional handbooks. Furthermore, the difference in infectivity between native varicella and subsequent herpes zoster is often misinterpreted. A disease entity with such disparate management strategies should be clarified. By summarizing the pathogenesis of herpes zoster and the efficacy of its treatment and vaccination, in addition to outlining the best practices given recent literature, dermatologists, physician extenders, and other medical providers will be better able to determine the appropriate course of treatment, isolation measures, and education of zoster patients.

Dorothee Nashan

Klinikum Dortmund gGmbH
Germany

Title: Actinic keratoses - A west European view

Time : 12:45-13:05

Speaker
Biography:

Dorothée Nashan is Professor and Head of Department of Dermatology, Klinikum Dortmund, Germany. She is specialist in dermato-oncology focus on melanoma, cutaneous lymphoma and palliative care. Her education included scientific work in biochemistry and immunology in reproductive medicine (Max Planck Society, Harvard Medical School), clinical education in the Departments of Dermatology, University of Münster and Fribourg. Continously publishing papers and serving as an editorial board member of repute she is engaged in the promotion and education of young colleagues inter alia in connection with the German Society of Dermatology.

Abstract:

High incidences of actinic keratoses, the pathophysiologically proven and accepted transition of AK into SCC and the resulting unacceptable mortality rate unify world-wide medical efforts in improving early diagnoses and therapies of AKs. A spectrum of efficient therapeutic options is available. Guidelines and recommendations from across Europe - Germany, Great Britain, France, Italy, and Spain – underline interest in the assessment, acceptance and use of therapeutic options, but also reveal diverse attitudes towards these aspects. Efforts to combat AKs include primary and secondary prevention. The evaluation of treatment includes a consideration of effectiveness, sustainability and tolerability of procedures, as well as response rates. An incredible number of publications concerning catchphrases like actinic keratoses, therapy, studies, response rate and spinalioma development complicate a survey. Useful up-dates, critical reviews and recommendations are continuously published. The number and grades of AKs, the size of area treated, and in particular the duration of follow-up are different, often making comparisons unbalanced. Cochrane based data analyses and meta-analyses confirm those difficulties whilst offering a ranking of standard interventions. Shouldn't we ask for a more normative procedure concerning the goals of our studies? Where is the common denominator in requirements? Besides personal expertise and equipment, the individual decision for the treatment of AKs should be based on the best possible evidence. Algorithms and increasing demand of sequential therapies will profit. All countries agree on the necessity of early treatment, and on the focus on point and field treatment, with increasing interest in long-term success, including in cases of field cancerisation. Implementation in daily practice and further requirements shall be discussed.

Break: Lunch Break 13:05-13:50 @ Cafe LaSalle
Speaker
Biography:

Maurice Efana Asuquo, FWACS, FICS, University of Calabar/University of Calabar Teaching Hospital, (UCTH),Calabar, Nigeria. Served as the Head of Department of Surgery, University of Calabar, Dean, Faculty of Medicine, and Dentistry and currently Provost College of Medical Sciences. His major research interest is dermatological oncology. Head of the Oncology unit of UCTH, Calabar, Nigeria. Attended several International and Local conferences, presented several papers on dermatological oncology and member of Dermatology-2014/ 2015-Organising Committee. He pioneered research resulting in over 80 publications.

Abstract:

Cutaneous metastasis is valuable though with infrequent occurrence in clinical practice. It is of esteem value in diagnosis as well as treatment of cancer due to the ease of accessibility for clinical examination and biopsy. Method Patients who presented with histologic diagnosis of cutaneous metastatic malignancies at the University of Calabar Teaching Hospital, (UCTH), Calabar, Nigeria from 2010 to 2013 were studied and compared with total number of patient with cutaneous malignancies seen over the same period. Results Sixty histologically diagnosed cutaneous malignancies presented to UCTH, Calabar, [55(92%) patients with primary cutaneous malignancies while 5(8%) were metastatic cutaneous cancer]. The 5 patients comprised 2 men and 3 women with ages that ranged from 37- 75 years (mean 59.2 years). The site distribution was 3(75%) anterior abdominal wall [2- umbilicus, Figure 1a, 1- laparotomy scar], 1- Back – left scapular region and 1 – wide spread cutaneous lesions (from head to the foot), Figure 2a. Two (40%) patients presented with malignant intestinal obstruction, Table 1. The histology of the cutaneous lesions revealed, 4 (80%) patients with metastatic adenocarcinoma, Figure 1b, 3 from proven colonic sites, one suspicious and one with metastatic olfactory neuroblastoma, Figure 2b. The later was the patient with wide spread cutaneous lesions. These nodules remarkably occurred during chemotherapy and radiotherapy for the primary left eye lesion that appeared to be responding to therapy. The outcomes were uniformly poor due to advanced primary lesions at presentation. Conclusion Evaluation of skin provides valuable insights into underlying malignant process and often of diagnostic and prognostic value. Clinicians are urged to show interest in cutaneous nodules in view of the estimable value by subjecting such for histological evaluation.

Speaker
Biography:

Andreia Ascenso has completed her Ph.D in Pharmaceutical Technology from Faculty of Pharmacy, University of Lisbon with final grade summa cum laude. She is Professor of Pharmaceutical Technology since September 2005. She has published and reviewed more than 10 papers in International Journals with peer review. She has 8 oral communications in reputed conferences. She serves as an Editorial Board Member on Carrier-Mediated Dermal Delivery: Applications in the Prevention and Treatment of Skin Disorders Book, Pan Stanford Publishing since 2014.

Abstract:

Introduction & Aims: Ultradeformable vesicles (UDV) have recently become a promising tool for the development of improved and innovative dermal and transdermal therapies with numerous advantages over the conventional delivery systems. The aim of this research work was to study three closely related UDV, Transfersomes (T), Ethosomes (E) and Transethosomes (TE) in different situations, such as a high, medium and low active incorporation efficiencies obtained with actives of distinct polarities (Vitamin E, Melatonin and Caffeine, respectively). Methods: The actives were incorporated in the three UDV formulations which characterization parameters corresponded to: the mean vesicles size and polydispersity index measured by photon correlation spectroscopy; zeta potential determined by laser-doppler anemometry; viscosity; deformability evaluated by pressure driven transport; active loading and entrapment yield determined by HPLC assay of each active before and after the separation of the non incorporated fraction by ultracentrifugation, and finally, incorporation efficiency in which the lipids assay was based on an enzymatic-colorimetric test. After this characterization, topical delivery studies were performed in order to compare the selected UDV formulations regarding the release, skin permeation and penetration profiles. Results: All UDV formulations showed size values within the expected range, except Transethosomes prepared by method A (“transfersomal” method), which size was less than 100 nm in contrast to what happened in method B (“ethosomal” method). Zeta potential was negative and higher for formulations containing sodium cholate. The Incorporation Efficiency was much higher for Vitamin E than Caffeine –loaded UDV as theoretically expected attending to the respective Log P. In general, it was obtained the following order for UDV flux: TE > E ≥ T. This result was consistent with the release and skin penetration profiles for Vitamin E- loaded UDV. However, the results were totally the opposite for Caffeine-loaded UDV, which might be explained by the solubility and thermodynamic activity of this active in each formulation instead of the UDV deformability attending to the higher non incorporated fraction of Caffeine. Conclusion: Attending to the results obtained, Transethosomes are more deformable than Ethosomes and Transfersomes due to the presence of both ethanol and surfactant in their composition. These UDV are suitable for a deeper skin penetration.

Speaker
Biography:

Hesham M Ahmad has completed his M.D. at the age of 25years and Ph.D. at the age of 32 years from Al-Minia University, Al-Minia, Egypt. He did his postdoctoral studies at Thomas Jefferson University School of Medicine, Philadelphia, PA, USA. He is the clinical director of Cocoon Medical Centre, Al-Ain, Abu Dhabi, U.A.E., a Dermatology and Aesthetic centre. He is also an assistant professor at Department of Dermatology at Al-Minia University Hospital, Al-Minia, Egypt. He has published more than 20 papers in reputed journals.

Abstract:

Acne vulgaris is a common condition that represents a physically and emotionally debilitating disorder and requires an adequate treatment. This work assess the clinical efficacy, side effects and laboratory changes of serum lipids and liver function during oral isotretinoin therapy for acne vulgaris, comparing single versus twice-daily dose regimens. 58 patients with acne vulgaris were included and classified into: Group I (26 patients) received once daily dose and Group II (32 patients) received a twice daily dose of oral isotretinoin. Global acne scoring system was used to objectively determine acne severity and to evaluate clinical improvement. Serum cholesterol, triglycerides, ALT and AST were evaluated before and 3 months after treatment. Both regimens resulted in highly significant improvement of acne scores but with no statistically significant difference in efficacy between the two groups. Incidence of clinical side effects, mainly dry skin and mucous membranes and gastro-intestinal upset, were significantly more common among patients receiving once daily dose. Both regimens caused mild but statistically significant rise of serum cholesterol, ALT and AST with more prominent rise in serum triglycerides especially with twice daily dose. In conclusion: Oral isotretinoin is very effective in acne vulgaris treatment with no statistically significant difference in clinical efficacy between once or twice daily doses. Clinical side effects are more common among patients receiving single daily dose. Both regimens cause mild but statistically significant rise of serum cholesterol, ALT and AST with more rise in serum triglycerides especially with twice daily dose.

  • Workshops
Location: Ground Ball Room B

Session Introduction

Erin E Boh

Tulane University
USA

Title: Psoriasis: Rethinking an ancient disease as Biochemistry & Immunology advances

Time : 10:30-12:30

Speaker
Biography:

Erin Boh MD PhD received her PhD in Biochemistry from Tulane University Medical School in 1980, and her MD in 1985 from Tulane. After completion of her residency in Dermatology at UT Southwestern Medical School, she started on faculty at Tulane University Health Sciences Center and has been on faculty since 1990. She currently is Professor of Dermatology and is chairman of the Department of Dermatology. Dr Boh has authored numerous peer reviewed articles, chapters in text books. She has served on numerous committees for the AAD, WDS. She is past president of the Louisiana Dermatology Society. She is currently on the Medical Board for National Psoriasis Foundation and is Board of Directors elect for the AAD.

Abstract:

This is a review of the developments in Biochenmistry and Immunology that have led to a clearer understanding of the pathogenesis of psoriasis and the mechanism of actions of pivotal biologics which are used to treat this chronic immune mediated disease.

Larry E Millikan

Tulane University
USA

Title: Drug Eruption

Time : 10:30-12:30

Speaker
Biography:

LEM trained at Univ Michigan served on faculty U Missouri (11years) and Tulane Founding chair (25 years) and has been emeritus since 2006. He serves as Secretary General of the IACD, is on several editorial boards and is active in the EADV, AAD, IACD, ASDS, and ISDS.

Abstract:

Drug eruptions have a wide spectrum of presentations, from Erythema and minimal urtication to the severe widespread mechano-bullous lesions as life threatening as third degree burns. Therefore early Dx and prompt Rx essential. This action template will be used in several presentations of reactions.

Speaker
Biography:

Baló-Banga (J. Mátyás) has graduated from Semmelweis Medical University, Budapest. After residency and specialization in dermatology-venereology he was assistant professor in the Dept. of Experimental Oncology at Indiana University Purdue University, Indianapolis. After returning from the US he defended his PhD Thesis in Budapest and became specialist in laboratory medicine and in allergy-immunology. Up to 1989 he participated in basic and clinical research with the Austrian Centre Seibersdorf. In the 1990-s he was elected as Secretary General of the Hungarian Dermatologic Society. After 28 years at the University Dermatology Department he became head of the Dermatology in the Military Hospital. He wrote or edited 20 books&book chapters and has ~40 papers cited in international medical databases.

Abstract:

Recently an International Consensus (ICON) on Drug Allergy has been published. This document includes skin and provocation tests in the diagnostic workup after drug eruptions but does not recommend in vitro assays because of lacking standardization. Humoral tests available on the market have low sensitivity, T-cell based cellular tests depend on cell cultures which last 3-5 days and have many requirements. Their results are often difficult to interpret for clinicians especially in relation of diverse phenotypic expression of drug induced skin injuries. Our aim was to overcome those problems by introducing a rapid reproducible assay based on preformed IL-6 release by the patients’ mononuclear cells. Earlier, detection of the culprit drug induced rapid changes was done by morphometry on T-cell nuclei after short exposure to simple media and using 4-10 sequential molarity based drug dilutions. The present methods included ELISA-based measurement of rapid specific release of IL-6 from isolated mononuclear cells upon 20 minutes incubation with 0.15-0.5 µM (final) solutions of pure drugs (mol.mass 76-4000 Da) with either PHA-P or ConA as positive controls. ConA increased IL-6 release in concentration and time dependent manner. This indicated a preformed cellular pool for this cytokine. The test results have reflected both severity and surface extensions only with culprit drugs (n=43) of various pharmacology and revealed a 85.4% sensitivity against in vivo challenges.

  • Track 6: Pediatric Dermatology
    Track 7: Diagnostic Techniques in Dermatology
    Track 8: Dermatological Oncology
    Track 9: Dermatology Therapies and Advances
Location: Ground Ball Room B
Speaker

Chair

Zachary A. Cooper

University of Texas MD Anderson Cancer Center, USA

Speaker

Co-Chair

Hector Ricardo Ralvan Garcia

Hospital Dermatology Dermoquirurgica, Mexico

Session Introduction

Aziz Ghahary

British Columbia Professional Fire Fighters
Canada

Title: A new hope in preventing the progression and treating Alopecia areata

Time : 13:15-13:35

Speaker
Biography:

Aziz Ghahary, PhD and Professor, the director of the BC professional Firefighters ‘Burn and Wound Healing Research Group has published more than 168 peer-reviewed articles some of which directly related to autoimmune diseases such as type I diabetes. Dr. Ghahary has been awarded more than 50 research grants from different local, national and international granting agencies. Dr. Ghahary is the leading investigator in identifying a serum 14-3-3 eta protein as a biomarker for early detection of RA and psoriatic RA and this test has now been launched by the Quest Diagnosis and Lifelab in US and Canada, respectively. Finally, he recently identified a small molecular with anti-scaring properties, which has now been approved by the Health Canada and the Vancouver General Hospital Ethic Committee to proceed to Phase 1 Clinical Trial.

Abstract:

Unfortunately, all treatment strategies currently used for Alopecia Areata (AA) are unsatisfactory. There are now supporting evidence that CD4+ and CD8+ T cells are involved in the pathogenesis of AA. Here, we targeted CD4+ and CD8+ by generating a L-tryptophan, an essential amino acid, deficient environment within which these cells can no longer become activated against hair follicle. To achieve this, we have successfully used IP injection of IDO, an enzyme that breaks down L-tryptophan to its metabolites, expressing cells in an AA mouse model and showed that none of AA affected mice developed AA as compared to 80% of control mice which developed extensive AA within 8-16 weeks after transplantation of an AA affected skin. The size of the lymph nodes in IDO treated mice was significantly smaller than that of non-IDO treated alopecia mice consistent with an absence of an inflammatory response. Importantly, this treatment significantly reduced the number of infiltrated immune cells (CD3+, CD4+ and CD8+ cells) at the site of AA affected skin as compared to that of controls. These findings indicate that IP injected IDO expressing dermal fibroblasts controls the inflammation and thereby reverses the progression of AA in this model. In conclusion, we have provided a supporting evince that the progression of AA can be prevented by using a novel strategy in generating a tryptophan deficient environment within which active CD4+ and CD8+ Tcells attacking hair follicles become dysfunctional and no longer are able to prevent the hair growth in our AA model.

Zachary A. Cooper

University of Texas MD Anderson Cancer Center
USA

Title: Understanding responses to therapy and rationale for combination strategies

Time : 13:35-13:55

Speaker
Biography:

Zachary A. Cooper completed his PhD from University of Maryland, Baltimore and postdoctoral studies from Brown University and Harvard Medical School. He joined the faculty at MD Anderson Cancer Center in 2013 with a dual appointment in the Departments of Surgical Oncology and Genomic Medicine. Dr. Cooper is a translational scientist whose research focuses on the interface of the immune system and targeted therapy in melanoma. He has published more than 30 manuscripts in reputed journals including Nature, Nature Genetics, Cancer Discovery, Journal of Clinical Investigations, Science Signaling, Cancer Research, and Clinical Cancer Research among others.

Abstract:

There have been significant advances in melanoma therapy over the past several years, with several molecularly targeted and immunotherapeutic agents recently FDA-approved for use the treatment of patients with metastatic disease. However with these advances, we are posed with therapeutic dilemmas with regard to timing and sequence of therapy. Namely, there is significant debate as to whether to begin treatment with targeted therapy versus immunotherapy upfront, and at which point to change treatment strategy. This is highly relevant, as each of these treatments as mono-therapy have significant limitations.
As a group, we have focused on better understanding response and resistance to therapy through longitudinal tissue and blood analyses in patients on targeted therapy and immunotherapy. We have worked with investigators worldwide to better understand response and resistance to therapy, and have gained critical insights that have led to therapeutic inroads for patients with melanoma. This includes the use of combination strategies, such as adding immune checkpoint blockade to a backbone of molecularly targeted therapy. Clinical trials combining these strategies are currently underway, and it is becoming increasingly apparent that complexities exist with regard to these combinations.
A better understanding of mechanisms of response to combination strategies through translational research is critical, and is best performed on longitudinal patient samples during the course of therapy, which may inform (and be informed by) parallel murine studies. Ultimately, ideal combination approaches will be built on a deep understanding of molecular and immune effects of each therapy in isolation, as well as in combination.

Speaker
Biography:

Robert Gensure completed his M.D. and Ph.D. at Tulane University School of Medicine and postdoctoral training at Massachusetts General Hospital. He is currently an Associate Professor at Albert Einstein College of Medicine and an attending physician at the Children’s Hospital at Montefiore. He has published more than 40 papers, review articles, and book chapters.

Abstract:

Alopecia is a very common condition with a variety of causes, including androgenic stimulation (male-pattern hair loss, polycystic ovarian syndrome), drug-induced (chemotherapy alopecia), and autoimmune disorders (alopecia areata). Hair loss can cause psychological stress, and the lack of effective therapies can cause patients to pursue off-label use of potentially hazardous treatments. Parathyroid hormone-related peptide (PTHrP) is a hair cycle regulator which provides a promising target for development of alopecia therapies. While early studies focused on using PTHrP antagonists to prolong the anagen phase, more recent studies suggest that PTHrP agonists can initiate the anagen phase by increasing levels of beta-catenin in hair follicles. Skin targeted PTHrP analogs have been shown to increase hair growth in animal models of chemotherapy alopecia and alopecia areata. The treatments result in increased number of hair follicles and resolve the dystrophic changes seen in these conditions. There is an associated increase in beta-catenin levels, which suggests that PTHrP agonists act through activation of the Wnt signaling pathway. This new finding introduces a promising target for drug development for many causes of alopecia.

Speaker
Biography:

Hector Ricardo Galvan Garcia has completed his MD at the age 25 years from Guadalajara University and postdoctoral studies from Institute of Dermatology of Jalisco. He is Director of Hospital Dermatology Dermoquirurgica in Jalisco, Mexico and he has published more 20 papers in reputed journals and serving as an editorial board member of repute.

Abstract:

In This study the effectiveness of laser therapy demostratedNy: YAG( 1064nm / 532nm) and pulse intensive light on the in vitro treatment of superficial mycoses, deep and atypical mycobacteria. Was performed in Petridishes with agar sabouraud cultures of t.rubrum, m.canis, t.tounsurans, t.mentagrophytes as well and deeperfungi, f.prodrosoi, s.schenki and c.carrioni, also sapphire glass tubes with culture médium lowenstein Jensen for m. abscessus.,allthese lumínicas exposing them to these two therapies. Finding in all cases a favorable response in inivicion growth of colonies, varying according to set this type of ligth, intensity, time and mechanics of it. Where by This reopening a new horizon in the dermatological therapeutics of the future.

Speaker
Biography:

Yasmine Issa has completed her MBSCh at the age of 24 from Alexandria Faculty of Medicine, then completed her MD and PHD. In 2008-2009, Yasmine was a research fellow in Leipzig University Clinic of Dermatology, Allergology and Venerology. Currently, she is a lecturer in Medical Biochemistry and Molecular Biology department, Alexandria Faculty of Medicine , where she resumes her postdoctoral studies. She is a researcher in nanomedicine lab, genomics center , and Egybiotech, a leading research incubator in Egypt. She is a reviewer in the journal “Andrologia”. She has publications and posters in the field of andrology, cardiovascular diseases,and nanomedicine.

Abstract:

Background: There is a strong body of evidence supporting an autoimmune basis forgeneralized vitiligo. B lymphocyte activating factor of the tumour necrosis factor family (BAFF)is known to be involved in the pathogenesis and progression of autoimmune diseases. Objective: To evaluate serum levels of BAFF and peripheral blood CD19+ Blymphocytes in patients with generalized vitiligo and to explore the effect of treatment withnarrow band ultraviolet B (NB-UVB) on their levels. Methods: Serum BAFF and peripheral blood CD19+ B lymphocytes were measured in30 patients with generalized vitiligo and 30 healthy control subjects. Patients received NB-UVBsessions for three months and follow up samples were then collected. Results: Serum BAFF and peripheral blood CD19+ B lymphocytes were significantlyhigher in patients than in control subjects (p<0.001). No significant correlation was detectedbetween serum BAFF and CD19+ B lymphocytes. In addition, correlations between serumBAFF or CD19+ B lymphocytes and disease duration, activity and severity were nonsignificant. After treatment with NB-UVB, significant reduction in the vitiligo area severity index (VASI)score was detected (p=0.02), but serum BAFF levels and Peripheral blood CD19+ Blymphocytes did not show significant change. Conclusion: Elevation in serum BAFF levels and CD19+ B lymphocytes in generalized vitiligo patients possibly provides further support to the autoimmune hypothesis of the disease and to the possible role played by B lymphocytes in the pathogenesis of the disease

Speaker
Biography:

Krystyna Mojsiewicz-Pieńkowska PhD, D.Sc is an Assistant Professor in the Department of Physical Chemistry at the Medical University of Gdansk, Faculty of Pharmacy with Subfaculty of Laboratory Medicine, Gdańsk, Poland.She is also an expert in the National Centre for Research and Development. She has published more than 25 papers in reputed journals.Krystyna Mojsiewicz-Pieńkowska is an active reviewer for the scientific pharmaceutical and chemical journals. Currently scientific and research activity is related with: studies of the penetration and permeation of silicones and drugs through the human skin; development of analytical methods for drug analysis; silicones application in pharmacy, medicine and cosmetic products

Abstract:

Skin diseases and dermatology problems depend on many factors. One of the reasons is the presence of various substances in medical products on skin, personal care products or cosmetics which are not indifferent for skin. For example, active pharmaceutical ingredients API and excipients can irritate the skin and cause allergic reactions, e.g. itchy rash, eruptions, atopic skin disease, other. However, sometimes patients or consumers do not have to feel any reaction but API or excipients can irreversibly change skin barrier. This is a very negative effect. First of all, the skin does not sufficiently prevent the entrance of noxious compounds or microorganisms. The damage the skin structure can cause to increase of the uncontrolled penetration into the stratum corneum and even permeate into the deeper layers of the skin of substances which can be toxicity. To the other hand, destruction of the organization the human skin structure impacts on the loss of semi-permeable skin barrier function for activity substances which are applied on the skin in treatment different diseases. The increase penetration, permeation and percutaneous substances absorption can be disturb of kinetics of drug delivery through the skin at a optimal rate. Apart from these, some chemical substances (as excipients) can cause to cytotoxic effect on cells. A new interdisciplinary approach is presented to demonstrate possibility of penetration the low molecular linear and cyclic methyl siloxanes (silicones) to human stratum corneum and permeation to the deeper layers of the skin (epidermis and dermis). On the basis of the fluorescence microscope as well as ATR FT-IR spectroscopy both the penetration and permeation to this skin layer as well as impact on damage of corneocytes of the stratum corneum was observed. It will be shown that the phenomenon alteration the skin barrier was due to damage of stratum corneum structure in conjunction with distinct disturbances in the lipid structure the mortar lipid of the stratum corneum. The results present that cyclic and linear methyl siloxanes are able to overcome the barrier of the skin due to interaction between silicones and bilayers SC lipids. At the end of the oral presentation the results concerning the cytotoxic effects for immortal keratinocytes cell line HaCaT are presented. These conclusions are very important for the safety of using these compounds, particularly in dermatology and toxicology. Low molecular linear and cyclic methyl siloxanes are commonly used as excipients in medical products for skin (e.g. Rozex Metronidazolum) and personal care products (e.g. Penaten Baby or Body Lotion Garnier). Apart from this they are used across a wide spectrum of personal care applications, including antiperspirants, skin, hair and nail care formulations, grooming products, sun protection products, personal lubricants, and cosmetic preparations. It causes the significant human exposure to this group of compounds. They can be applied both by adults, children and infants. It must notice that so far, the transdermal route has not been described in the literature as a possible route of penetration and permeation by the linear and cyclic methyl siloxanes. ACKNOWLEDGMENTS This project was supported by Polish Ministry of Science (The National Centre for Research and Development NCN, grant 2013/11/B/NZ7/02076)

Daudi Rajabu Mavura

Kilimanjaro Christian Medical University College
Tanzania

Title: Initiation of antiretroviral therapy in HIV-infected adults with skin complaints in northern Tanzania

Time : 15:15-15:35

Speaker
Biography:

Daudi Mavura is the current principal of the Regional dermatology training center (RDTC) in Moshi, Tanzania where he also lectures.The RDTC is a tertiary training institute of both The Tumaini University and Muhimbili University of Health sciences. Dr. Mavura holds a Medical Degree from the University of Carlos J. Finlaty in Cuba and a Masters of Medicine degree from the Tumaini University .He has subspecialised in dermatosurgery from UKT-Germany and the Univesida de alcala de Henare in Spain. He has published and co-authored several papers mostly in tropical dermatology. He is fluent in English, Spanish and his native Kiswahili.

Abstract:

Abnormal skin findings are identified in over 90% of human immunodeficiency virus (HIV) - infected persons globally. A prospective cohort study of HIV-infected subjects presenting with skin complaints in northern Tanzania was undertaken. Consecutive HIV- infected subjects presenting with skin complaints, who met criteria for ART initiation, were recruited at a Tanzanian Regional Dermatology Training Center. A single dermatologist evaluated all subjects; baseline skin biopsies were performed, and CD4+ cell counts and plasma HIV RNA levels were measured. All subjects received a fixed – dose combination of stavudine, lamivudine, and nevirapine. A total of 100 subjects were enrolled; 86 subjects completed six months of follow-up. Median baseline CD4+ cell counts and plasma HIV RNA levels were 120 cells/ul and 5.2 log10 copies/ml. The most common dermatological condition was papular pruritic eruption (47%). The median baseline score on the burn scale was 38%. After six months, 10 subjects had achieved the complete resolution of the skin abnormalities. In those without complete resolution, the median Burn Scale score improved to 7 %. Five patients developed new eruptions by month 3, which in two cases were attributed to drug reactions. In the 86 subjects remaining on ART after the six months, the median CD4+ cell count had increased to 474 cells/ul and plasma HIV RNA levels were <400 copies/ml in 85 ( 99%) subjects. Patients with HIV infection with skin complaints experienced marked clinical improvements following ART initiation.

Break: Networking & Refreshments Break 15:35-15:50 @ Foyer
Speaker
Biography:

Claudia Sa Guimaraes has completed his graduation in Medicine at the age 24 years from Souza Marques School Medicine and specialization in dermatology at Rio de Janeiro Santa Casa de Misericordia. She has published 3 books, more than 4 chapter on dermatology text books, three articles in reputed journals and worked at Brazilian journal of Medicine 14 years. Since 2011 have been collabored with Federal University of Rio de Janeiro at Laboratory of Celular Biology of Fungus where Taissa Villa with Sonia Rozental supervision create a new model of in vitro fungal biofilms emerged from the interest on the laser treatment of onychomycosis in your doctor's office.

Abstract:

Onychomycosis represent approximately 50% of all nail diseases worldwide. In warmer and more humid countries like Brazil, the incidence of onychomycosis caused by non-dermatophyte molds (NDM, including Fusarium spp.) or yeasts (including Candida albicans) has been increasing. Traditional antifungal treatments used for the dermatophyte-borne disease are less effective against onychomycosis caused by NDM. Although some laser and light treatments have demonstrated clinical efficacy against onychomycosis, their FDA-approval as 'first line' therapy is pending, partly due to the lack of well-demonstrated fungicidal activity in a reliable in vitro model. Here, we describe a reliable new in vitro model to determine the fungicidal activity of laser and light therapy against onychomycosis caused by Fusariumoxysporum and C. albicans. Biofilms formed in vitro on sterile human nail fragments were treated with 1064-nm neodymium-doped yttrium aluminum garnet laser (Nd:YAG), 420 nm intense pulsed light (IPL 420), IPL 420 followed by Nd:YAG, or near infrared light (NIR 700 - 1400 nm). Light and laser antibiofilm effects were evaluated using cell viability assay and scanning electron microscopy (SEM). All treatments were highly effective against C. albicans and F. oxysporum biofilms, resulting in decreases in cell viability of 45-60% for C. albicans and 92-100% for F. oxysporum. The model described here yielded fungicidal activities that matched more closely those observed in the clinic, when compared to published in vitro models for laser and light therapy. Thus, our model might represent an important tool for the initial testing, validation and 'fine-tuning' of laser and light therapy against onychomychosis.

  • Track 3: Cosmetic Dermatology
    Track 4: Herbal Dermatology
    Track 5: Dermatological Therapeutics
Location: Ground Ball Room B
Speaker

Chair

Philip W Wertz

University of Iowa College of Dentistry, USA

Speaker

Co-Chair

Farrokh Khosravi

Texas Institute of Dermatology, USA

Session Introduction

Philip W. Wertz

University of Iowa College of Dentistry
USA

Title: Antimicrobial lipids at the skin surface

Time : 14:50-15:10

Speaker
Biography:

Philip W. Wertz is a Professor in the Dows Institute, which is part of the University of Iowa College of Dentistry. He has more than 150 publications in refereed journals and numerous book chapters. He serves on several editorial boards

Abstract:

The skin surface represents our interface with the external environment, and as such, is our first line of defense against microbial colonization and infection. Lipids at the skin surface are thought to underlie at least part of an antimicrobial barrier. The skin surface is coated with sebaceous lipids, including lauric acid (C12:0) and sapienic acid (C16:1Δ6), both of which are uniquely potent antimicrobial agents. The free fatty acids are produced through the action of lipase(s) on sebaceous triglycerides. In addition, the stratum corneum contains antimicrobial free long-chain bases, sphingosine and dihydrosphingosine. The long-chain bases are thought to be produced through the action of ceramidases on ceramides near the skin surface. These antimicrobial lipids have been shown to kill a range of Gram-positive and Gram-negative bacteria, including Staphylococcus aureus that is resistant to both methicillin and mupirocin. Furthermore, some of these lipids have been found to act synergistically with ethanol and with the antimicrobial peptide LL37. In fact, sapienic acid, with or without a low concentration of ethanol, was more effective than mupirocin. These lipids are thought to be part of the innate immune system of the skin. The possibility exists that topical formulations of these lipids could be used prophylactically to prevent infections in susceptible individuals, such as the elderly or people with atopic dermatitis. Such formulations could also be used to treat active infections.

Speaker
Biography:

Farrokh Khosravi, M.D., has completed his fellowship of Rheumatology at the age of 38 years from Shiraz University. He is a part time Assistant Professor of Medicine. His field of interest is autoimmune skin disease and has published several papers in peer reviewed journals and served as a reviewer for Various Medical Journals.

Abstract:

Drug induced osteoporosis (DIO) represents about 20% of all cases affected by Osteoporosis. DIO is one of the most challenging health issues in the elderly patients affected by various skin diseases. Any attempt to prevent or treat DIO will significantly decrease patients’ morbidity and mortality. Novel drugs have been recently developed for prevention and/or treatment of DIO. New methods of detection, prevention and treatment of DIO will be discussed.

Umit Tursen

Mersin University School of Medicine
Turkey

Title: Evidence-based treatment in Behcet’s diseases

Time : 15:30-15:50

Speaker
Biography:

Umit Tursen was born in Turkey. He graduated from Gazi University Faculty of Medicine as Medical Doctor. He completed the residency period of Dermatology in Ankara University, Faculty of Medicine, and Department of Dermatology between 1995-1999. He has been working in Mersin University, School of Medicine, and Department of Dermatology since 2000. He is the Director of Mersin University, School of Medicine, and Dermatology Department. He has published more than 80 papers in reputed journals, also books and serving as an editorial board member of repute. He won Behcet’s disease research award of “The scientific and technical research council of Turkey (TUBITAK)” in 1999. He is married and he has 2 children.

Abstract:

Behcet's disease (BD) is a chronic, relapsing, systemic vasculitis of unknown etiology with the clinical features of mucocutaneous lesions, ocular, vascular, articular, gastrointestinal, urogenital, pulmonary, and neurologic involvement. Mucocutaneous lesions figure prominently in the presentation and diagnosis, and may be considered the hallmarks of BD. Therefore, their recognition may permit earlier diagnosis and treatment. Although, the treatment has become much more effective in recent years, BD is still associated with severe morbidity and considerable mortality. The main aim of the treatment should be the prevention of irreversible organ damage. Therefore, close monitoring, early and appropriate treatment is mandatory to reduce morbidity and mortality. Traditional and current treatments with topical, paraocular and systemic corticosteroids, colchicine, dapsone, cyclosporine, azathioprine, methotrexate, cyclophosphamide and chlorambucil are summarized and recent insights into the pharmacology and effects of thalidomide, tacrolimus (FK-506), interferon-α, anti-TNF-α blocking monoclonal autoantibody (infliximab) and soluble TNF receptor (etanercept) are reviewed. We reviewed the current state of knowledge regarding the therapeutic approaches for BD and designed a stepwise, symptom-based, algorithmic approach, mainly based on controlled studies and our clinical experience in this field to provide a rational framework for selecting the appropriate therapy along the various treatment choices. Key clinical investigations with the status of ongoing clinical trials aimed at addressing the drug’s efficacy, surgical care, and studies that have raised the possibility of new therapeutic uses are also presented. The challenges posed by the drug’s teratogenicity and adverse effects are also considered, if present.

Hector Ricardo Galvan Garcia

Hospital Dermatology Dermoquirurgica
Mexico

Title: Onychomycosis: 1064-nm Nd: YAG q-switch laser treatment

Time : 15:50-16:10

Speaker
Biography:

Hector Ricardo Galvan Garcia has completed his M.D.at the age 25 years from Guadalajara University and postdoctoral studies from Institut of Dermatology of Jalisco. He is director of Hospital Dermatology Dermoquirurgica in Jalisco, Mexico and he has published more 20 papers in reputed journals and serving as an editorial board member of repute.

Abstract:

Laser treatment of onychomycosisis a quick and easy method without complicationes. Two hundred patients with a KOH(+) , onychoscopy(+), confirmed clinical diagnosis of onychomycosis were included in the present study. All of the patients were treated in a single sesión with a 1064-nm neodymium-dopedyttrium-aluminumgarnet (Nd:YAG)q-switch laser. There was a 100% clinical response rate within the 18-month follow-up period with no side effects. This method is proposed as a novel and safe method for the treatment of ungualpathology.

Speaker
Biography:

Mani Kumar Sharma did his MBBS from Kolkata University, India and completed his MD from Utkal University, India. He is presently the director of Sharma Skin Foundation, Siliguri India, a premier skin foundation of eastern India. He is also the President of North Bengal Unit of Indian association of Dermatologists, Venereologists and Leprologists. He has been an original scientific research worker and has more than 20 publications in reputed journals to his credit. His works on mycoses and Pure Neuritic Leprosy in rural India are invaluable.

Abstract:

Objective: To study the role of ultrasonography (USG) of nerves as a screening and follow up imaging modality in clinically suspected cases of Pure Neuritic Leprosy (PNL). Materials and Methods: Peripheral nerves of 450 clinically suspected cases of Pure Neuritic Leprosy were evaluated by high resolution ultrasonography and compared with histologic findings. The cases were categorized according to the USG criterias-echogenicity of nerves-echogenic, hypoechoic and hyperechoic, thickness of nerves-normal and suspected nerves were compared. Results: The analysis showed that 88% of hyphoechoic and thickened nerves showed AFB in histology. 38% of hypoechoic nerves without thickening showed AFB in histology. Nerve abscess was seen in 3% of cases. 40% of after treatment showed misted echogenicity. Conclusion: Ultrasonography (USG) can be used as a screening and follow up imaging modality in suspected cases of Pure Neuritic Leprosy (PNL) in endemic areas as it is a non-invasive, easy to use, cheap, sensitive and highly reliable tool. References: High resolution sonography of the peripheral nervous system, a review of literature; European journal of neurology 11 (5) 305-314; Echotexture of peripheral nerves correlation between Ultrasonography and histologic findings; Radiology, 1995 vol. 197 pp 291-296.

Break: Networking & Refreshments Break 16:30-16:45 @ Foyer
Speaker
Biography:

Jing Shang has completed his Ph.D at the age of 33 years from Free University of Berlin in Germany. She is the deputy director of Center for Drug Screening, China Pharmaceutical University and the secretary general of Applied Pharmacology Committee, Chinese Pharmaceutical Association. She has published more than 100 papers in reputed journals and serving as an editorial board member of repute.

Abstract:

Skin disease belongs to a complex disease, such as vitiligo, psoriasis, alopecia areata, atopic dermatitis, etc. Its specific mechanism is so far unclear. There is a great difficulty in treatment, enough to cause much pain to the patient. Skin is as the largest organ of the human body. Its existence is not just for the body barrier to the outside threatened homeostasis, and the skin and its accessories is widely innervated, the sensory nerve in the skin is directly upward to the cerebral cortex. The skin can be independent to synthetize and secret the stress hormones to maintain local and systemic homeostasis, and is also one of the biggest target organs of these hormones. Taken together, the skin is as the body's largest neuroendocrine and immune organs. Clinical survey found that the onset and development of many skin diseases were closely related to mental factors. A variety of skin diseases are contributed to the liability under psychological stress, such as urticant, atopic dermatitis, urticaria, psoriasis, acne, hair loss, etc. Mental stress can induce or aggravate the skin disorders. Psychological soothing and keeping a good state of mind can both help to alleviate these diseases. Now, for the pathogenesis analysis of these diseases, a preliminary study suggests that these skin diseases including psoriasis, vitiligo, alopecia areata, atopic dermatitis, etc., indeed have associations with mental stress. When the body responds to mental stress, the skin will present a corresponding change, such as hot flashes, sweating, etc. In addition to these visible external reactions, we also found that the skin showed significantly increased immune cells and mast cell degranulation. Large number of experimental and clinical studies proved that mental stress involved in the development and progression of many skin diseases. In response to mental stress, the body starts the hypothalamus - pituitary - adrenal (HPA) axis to combat stress conditions. Meanwhile, skin has its own HPA axis to respond to external stress and regulate skin function such as melanogenesis. Therefore, there is a problem that how HPA axis mediates the effect of mental stress on skin function, so as to promote the occurrence and development of skin diseases. To study the skin's response in face of mental stress and to explore the etiology and pathogenesis of skin diseases related to mental factors, it is of great significance and importance to the exploration of treatment targets and methods involved in skin disease. This topic aims to study on the role of HPA axis in mental stress affecting skin functions, and investigate the mechanism of natural medicine HZCZ for regulating skin functions in a multi-target manner. This study provides a new idea of drug development for complex disease.

Speaker
Biography:

Arpi Avetisyan is a Research Associate at Nairian CJSC, an Armenia-based all-natural cosmetics manufacturer. Her primary responsibility in the company is technology development for production and scientific research in the field of herbal cosmetics. Arpi is interested in safe use of various herbs and essential oils to address diverse cosmetology issues. Before joining Nairian CJSC, Arpi was a Researcher at the Institute of Chemical Physics of NAS of Republic of Armenia. She obtained her MS degree in Chemistry from Yerevan State University, Yerevan, Armenia.

Abstract:

The aim of this study was to analyze the chemical composition of essential oils from three different species of basil, O.basilicumpurpureum('Purple basil'), O.basilicumthyrsiflora('Thai basil'), and O. citrodorum ('Lemon basil'),and to test their biological activities. The three basil species were cultivated in the same field, at the elevation of 1600m above sea level, in the Kotayk Region of Armenia. The essential oils were obtained by steam distillation in a Clevenger-type apparatus, a HP GC-MS setup was used to determine their chemical composition. According to the results, Purple basil essential oil contained 57.3% of methyl-chavicol (estragol); Thai basil oil had 68.0% of linalool and the main constituents of Lemon basil oil were nerol (23.0%) and citral (20.7%). The antioxidant activities of these essential oils were measured using DPPH assays. The highest antioxidant activity was demonstrated by Thai basil essential oil: IC50 value for it was equal to the standardized Grapefruit Seed Extract used as a control sample. The tyrosinase inhibition abilities of all three oils were also assessed. Obtained data indicate that basil essential oils can be useful natural agents for cosmetic applications and food dietary supplements. To test the possibilities for cosmetic application, several synergistic mixes containing essential oils from all three basil species were created and added to cosmetic cream bases. The oil mixes used in the creams were designed taking into account the dermal maximum values defined for their constituents ["Essential Oils Safety", Tisserand&Young, 2014]. The creams were used for in-vivo testing on volunteers.

Sevil Alan

Akdeniz University
Turkey

Title: Acne and treatment

Time : 17:25-17:45

Speaker
Biography:

Sevil Alan was born in Burdur, Turkey, in 1978. She received her medical degree from Ege Medical School in Ä°zmir, Turkey and completed his dermatology residency at the Adana Numune Education and Research Hospital in Adana, Turkey. Today, Dr. Sevil Alan is a specialist of dermatology at the Akdeniz University School of Medicine, Antalya.

Abstract:

Acne vulgaris is a chronic inflammatory skin disease that effects the pilosebaceous unit and is characterized with comedones, papules, pustules, nodules and occasionally with scars. The mainstay of acne therapy includes: topical retinoids, topical antibiotics, benzoyl peroxide (BP), and oral isotretinoin for severe cases. Current acne treatment regimens often require patients to use multiple medications, some of which may have side effects. Many of the new therapies discussed in this presentation.

Ufuk Kavuzlu

Mersin University Faculty of Medicine
Turkey

Title: Off Label uses of vitamin-D treatment in Dermatology

Time : 17:45 -18:05

Speaker
Biography:

Ufuk Kavuzlu received his medical degree from Mersin University in 2011, at the age of 24. Since 2013 he is an assistant doctor in Mersin University Hospital which his ongoing residency training in dermatology has started in.

Abstract:

Vitamin D is used in patients with psoriasis for years since it provides keratinocyte proliferation and differentiation regulation it can also be used in skin diseases other than psoriasis.The aim of the study is to detect the off-label use of vitamin D in the skin diseases. All data about off label uses of vitamin D in treatment in dermatology were screened on medline database. Obtained studies were grouped according to types of diseases. 60 articles were included in the study. Strong evidences are found that the topical use of vitamin D in vitiligo as a part of combined therapy is effective. It is also showed that use of vitamin D as topical treatment has beneficial effect in several skin diseases such as morphea, eritema annulare centrifugum, prurigo nodularis, warts, ichtyosis; and as systemic treatment in diseases such as granuloma annulare.Vitamin D is not only effective in psoriasis, but also in the treatment of many skin diseases due to regulatory effect on keratinocytes and immunoregulatory properties. But still more comprehensive studies about off label use of vitamin D in dermatology is required.

  • Workshop
Location: Ground Ball Room B

Session Introduction

Moris Topaz

The Technion, Israel Institute of Technology Israel

Title: Changing the standards of wound care: New concepts for treatment of minor and large wound defects
Speaker
Biography:

Moris Topaz, has completed his MD., and PhD at the Ben Gurion University, Israel and postdoctoral Fellowship at the Eastern Virginia Graduate School of Medicine, USA. He is the director of the Plastic Surgery Unit, the Hillel Yaffe Medical Center and was affiliated for years to the Department of Chemistry, Bar Ilan University, Israel. Dr. Topaz has developed innovative devices and technologies to expedite wound healing. He has written and published articles in a variety of medical journals, and has actively participated in numerous scientific meetings globally. Currently he is leading a national project in wound healing in China as a visiting foreign expert professor.

Abstract:

Stress-relaxation is a well-established mechanism for laboratory skin stretching, with limited clinical application in conventional suturing techniques due to the inherent, concomitant induction of ischemia, necrosis and subsequent suture failure. Skin defects that cannot be primarily closed are a common difficulty during reconstructive surgery. The TopClosure® tension-relief system (TRS) is a novel device for wound closure and secure, attaching to the skin through a wide area of attachment, in an adjustable manner, enabling primary closure of medium to large skin defects. We present demonstrative cases requiring resection of large to huge tumors customarily requiring closure by skin graft or flaps. TRS was applied during surgery serving as a tension-relief platform for tension sutures, to enable primary skin-defect closure by cycling of stress-relaxation, and following surgery as skin-secure system until complete wound closure. All skin defects were manipulated by the TRS through stress-relaxation, without undermining of skin, enabling primary skin closure and eliminating the need for skin grafts and flaps. Immediate wound closure ranged 26 – 135 min. Complications were minimal and donor site morbidity was eliminated. Surgical time, hospital stay and costs were reduced and wound aesthetics were improved. TRS is novel technology that enables the utilization of the viscoelastic properties of the skin to an extreme level, extending the limits of primary wound closure by the stress-relaxation principle. This is achieved via a simple device application that aid immediate primary wound closure and downgrade the complexity of surgical procedures for a wide range of applications on a global scale.

  • Special Session
Location: Ground Ball Room B
Biography:

Alexander Zink, M.D., M.P.H. is a Dermatologist and Public Health Specialist at the Department of Dermatology and Allergy at Technische Universität München in Munich, Germany. His research interests include public health and prevention strategies in dermatology and new treatment approaches in dermatologic diseases with main focus on immunoadsorption. He has published multiple peer-reviewed articles in highly ranked international journals and served as a specialist for immunoadsorption on several past international meetings.

Abstract:

Patients severely affected by atopic dermatitis (AD) commonly have highly elevated serum IgE levels. Until today, the role of IgE in the pathogenesis of AD remains a highly controversial issue. To evaluate the role of IgE in AD we developed an anti-IgE-treatment approach by combining immunoadsorption (IA) and anti-IgE antibody omalizumab (OMZ) for maximum possible IgE serum level reduction in patients with severe, therapy-refractory AD and elevated IgE levels. First patients treated by IA and OMZ all showed an significant reduction of IgE-levels after IA and a further dropping of biological active IgE during treatment with omalizumab. A reverse trend was observed after stopping treatment during the follow-up period. Parallel, a clear improvement of AD was seen during the treatment period followed by an aggravation during observational follow-up. Combining IA and OMZ in atopic dermatitis thus seems suitable to effectively reduce elevated serum IgE levels and to improve clinical symptoms of severe refractory AE without other systemic treatments. However, further studies with larger patient numbers are needed to strengthen our conclusion based on the first findings of our novel and promising anti-IgE treatment approach in severe atopic dermatitis.